U.S.-Based Biotech Axiom Biosciences Plans Primary Listing in Hong Kong Before U.S.
Axiom Biosciences, a San Diego-based biotechnology company developing regenerative and genetic medicines, plans to pursue its primary public listing on the Hong Kong Stock Exchange by 2027 before seeking a secondary listing in the United States in 2029. The decision reflects growing interest among global biotech firms in leveraging Hong Kong's expanding investor base and proximity to Chinese pharmaceutical partners for faster trials and lower costs.
Tickers: $BABA
Topics: biotech capital raising hong kong listing u.s. secondary listing